Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Cytokinetics, Incorporated

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving landscape of corporate finance, understanding operational costs is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two distinct companies: Walgreens Boots Alliance, Inc. and Cytokinetics, Incorporated, from 2014 to 2023.

Walgreens Boots Alliance, Inc.

Walgreens, a retail giant, consistently reported SG&A expenses exceeding $17 billion annually. Notably, from 2014 to 2023, their expenses grew by approximately 44%, peaking in 2024. This trend reflects the company's expansive operations and strategic investments.

Cytokinetics, Incorporated

In contrast, Cytokinetics, a biopharmaceutical firm, exhibited a more volatile SG&A trajectory. Starting at $17 million in 2014, their expenses surged over 900% by 2023, highlighting aggressive R&D and market expansion efforts.

This comparative analysis underscores the diverse financial strategies of a retail behemoth and a biotech innovator, offering insights into their operational priorities and market dynamics.